{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","spread":"7.07","value":"38"},{"groupId":"OG002","spread":"80.48","value":"55.3"},{"comment":"Standard deviation cannot be estimated for one participant.","groupId":"OG003","spread":"NA","value":"27.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"description":"Time to best objective response was defined as time from the date of brexucabtagene autoleucel infusion to the date of best response per the Sixth International Workshop in WM for r/rWM, per the Lugano Classification for r/rRT and r/r BL, and per Grever and colleagues for r/rHCL. Objective response (OR) is defined in OM#25 (Substudy B), 28 (Substudy C), and 29 (Substudy D).","dispersionType":"Standard Deviation","groups":[{"description":"This substudy was withdrawn; therefore, no participants were enrolled.","id":"OG000","title":"Substudy A (Relapsed/Refractory Waldenstrom Macroglobulinemia): Brexucabtagene Autoleucel"},{"description":"Participants with Relapsed/Refractory Richter Transformation received the following treatment during the study:\n\nLymphodepletion chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3). A single IV infusion of brexucabtagene autoleucel at target dose of 2 × 10\\^6 anti-CD19 CAR T cells/kg on Day 0.","id":"OG001","title":"Substudy B (Relapsed/Refractory Richter Transformation): Brexucabtagene Autoleucel"},{"description":"Participants with Relapsed/Refractory Burkitt Lymphoma received the following treatment during the study: Lymphodepletion chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3). A single IV infusion of brexucabtagene autoleucel at target dose of 2 × 10\\^6 anti-CD19 CAR T cells/kg on Day 0.","id":"OG002","title":"Substudy C (Relapsed/Refractory Burkitt Lymphoma): Brexucabtagene Autoleucel"},{"description":"Participants with Relapsed/Refractory hairy cell leukemia received the following treatment during the study: Lymphodepletion chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3). A single IV infusion of brexucabtagene autoleucel at target dose of 2 × 10\\^6 anti-CD19 CAR T cells/kg on Day 0.","id":"OG003","title":"Substudy D (Relapsed/Refractory Hairy Cell Leukemia): Brexucabtagene Autoleucel"}],"paramType":"MEAN","populationDescription":"Participants in substudies B, C and D, in the Modified Intent-to-Treat Analysis Set with objective response were analyzed. Substudy A was withdrawn, therefore no participants were enrolled in it. Hence, data is not available.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"All Substudies (Substudies A, B, C and D): Time to Best Objective Response","type":"SECONDARY","unitOfMeasure":"days"}